Anti-CD19 x Anti-CD89 Bispecific Antibody (IgG-IgG) (BSIG-045)

Anti-CD19 x Anti-CD89 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD19 and anti-CD89 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget macrophages to tumor cells. It is designed for the research of B cell lymphoma; Leukemia therapy.

Datasheet INQUIRY

Specifications

Targets

CD19 & CD89

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma; Leukemia

Targets

Target 1

CD19

Gene ID

930

UniProt ID

P15391

Alternative Names

CD19; CD19 molecule; Cluster of differentiation 19; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4

Target 2

CD89

Gene ID

2204

UniProt ID

P24071

Alternative Names

FcαRI; FCAR; Fc fragment of IgA, receptor for; CD89; FcalphaRI; immunoglobulin alpha Fc receptor; Fc alpha receptor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD19 x Anti-CD89 Bispecific Antibody (IgG-IgG) (BSIG-045). Click the button below to contact us or submit your feedback about this product.

Anti-CD19 x Anti-CD89 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-045)

Specifications

Targets

Customer Reviews and Q&As